Arrowhead has not initiated research coverage on Nicox S.A. yet.

About
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Their strategy is to become a fully integrated pharmaceutical company focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye...
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Their strategy is to become a fully integrated pharmaceutical company focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye diseases. This strategy includes advancing Nicox's product candidates through clinical development to approvals in the U.S., optimizing the development through partnerships, maximizing the value of our product ZERVIATE through collaborations and expanding their product candidate pipeline through internal research efforts and potential in-licensing activities or acquisitions of additional ophthalmic product candidates or products.
  • 19
    Oct
    21
    News Release
    Nicox Provides Third Quarter 2021 Business and Financial Highlights
  • 13
    Oct
    21
    News Release
    Nicox to present at the OIS Glaucoma Virtual Innovation Showcase
  • 4
    Oct
    21
    News Release
    Nicox Launches New Corporate & Investor Website
  • 29
    Sep
    21
    News Release
    Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model
  • 27
    Sep
    21
    News Release
    Nicox First Half 2021 Financial Results and Business Update
  • 23
    Sep
    21
    News Release
    Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial
  • 20
    Jul
    21
    Company Presentation
    Nicox Corporate Presentation
  • 16
    Jul
    21
    News Release
    Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update
  • 13
    Jul
    21
    News Release
    Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board
  • 6
    Jul
    21
    Company Presentation
    Nicox Investor Presentation
  • 5
    Jul
    21
    News Release
    Nicox to Receive US$2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE Agreement
  • 2
    Jul
    21
    News Release
    Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial
  • 1
    Jul
    21
    News Release
    NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial
  • 25
    Jun
    21
    News Release
    Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates
  • 23
    Jun
    21
    News Release
    Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021
  • 1
    Jun
    21
    Company Presentation
    Nicox S.A. Corporate Presentation
  • 5
    May
    21
    Company Presentation
    Nicox Corporate Presentation
  • 5
    May
    21
    News Release
    Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico
  • 4
    May
    21
    News Release
    Nicox’s Licensee Bausch + Lomb Launches VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
  • 30
    Apr
    21
    News Release
    Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod
  • 27
    Apr
    21
    News Release
    U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma